Veracyte, Inc. (VCYT)

Veracyte's stock (VCYT) traded between $50.71 and $22.61 over the past six months, with a price around $34.86 in early February 2026. Strong earnings reports, such as Q3 2025 EPS of $0.51 and revenue of $131.87 million, and raised full-year 2025 revenue guidance to $506-$510 million, impacted the stock positively. Analysts have given VCYT an average "Hold" rating with a mean 12-month target price of $46.14. Insiders sold 134,635 shares totaling approximately $5.98 million. Product developments include the launch of Decipher for metastatic prostate cancer and the upcoming launch of Prosigna as an LDT for the US breast cancer market.

There is no explicit mention or indication of significant demand seasonality for Veracyte, Inc.'s products and services. The company's earnings reports and business updates consistently highlight overall growth in testing volumes and revenue across quarters, rather than specific seasonal fluctuations.

Veracyte, Inc. is a genomic diagnostics company focused on improving patient care through high-value insights for diagnosing and treating cancers and interstitial lung diseases. Their core business involves genomic diagnostic products and services aimed at resolving diagnostic ambiguity and avoiding unnecessary procedures. Key products include Afirma Thyroid FNA Analysis, Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier, Decipher Prostate Genomic Classifier, Decipher Bladder Genomic Classifier, Prosigna Breast Cancer Assay, Lymphmark, and TrueMRD. The company's platform uses genomic assays, clinical data, AI-assisted data mining, and evidence generation to deliver diagnostic innovation.

Veracyte is a global diagnostics company aiming to transform cancer care worldwide. Starting in South San Francisco, California, with significant revenue from the United States, it has expanded to include a European presence through acquisitions like HalioDx. The company operates in the US, France, and Israel, employing a hybrid global approach with central lab testing in the US and a distributed In Vitro Diagnostic (IVD) model for international markets.

Veracyte's brand reputation is strong, built on its mission to transform cancer care globally by providing clinicians with high-value genomic insights. Consistent double-digit revenue growth, strong clinical adoption serving over 800,000 patients, strategic acquisitions and product launches, a record adjusted EBITDA margin of 30% in Q3 2025, and inclusion of tests in clinical guidelines have positively affected the company's reputation and market standing.

Veracyte, Inc. is a publicly traded company with ownership distributed among institutional and individual investors. Institutional investors hold a significant majority of the shares, with 555 institutional owners holding 108,866,339 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Artisan Partners Limited Partnership. Individual insiders hold approximately 0.408% or 361,350 shares.